Navigation Links
2007 Life Sciences Compensation Findings Disclosed www.compstudy.com
Date:11/27/2007

BOSTON, Nov. 27 /PRNewswire/ -- J. Robert Scott, a leading retainer-based executive search firm; Ernst & Young, a global leader in professional services; and the internationally recognized law firm of WilmerHale; in collaboration with professors from Harvard Business School, have released data for their 2007 Compensation & Entrepreneurship Report in Life Sciences, available at http://www.compstudy.com. This study is a valuable tool in helping businesses and executives understand today's ever-changing compensation trends for senior executives within privately-held therapeutic, diagnostic, medical device, instrumentation and platform companies.

"Being aware of changing compensation trends allows businesses to understand the executive talent pool and to better align their compensation strategies and programs with current market conditions," commented J. Robert Scott Managing Director Bruce Rychlik. "The compensation study includes significant data on cash compensation, equity holdings, base salaries and bonuses. In the past, reliable equity and cash compensation figures have only been available for public biotechnology companies. Compstudy.com provides much-needed statistics on the changing dynamics for senior executives within private, venture-backed life science companies."

Five key findings were identified in this year's survey:

-- Salary and Bonus: Total target cash for the CEO rose 2% year over year,

most notably in base salary, an increase of $11,000. Average base

salary rose by 5.9% across the executive positions surveyed from 2006

to 2007. Average target bonus remained largely unchanged year over

year.

-- Equity Holdings: Option grants continue to dominate as vehicles used

for the executive team. Incentive stock options account for just over

half of the equity grants to the management team in 2007, down from 62%

from our 2006 report.

-- Recruiting and Retention: As companies evolve from the early stage,

with one or fewer rounds of funding, to becoming more mature companies

with four or more rounds of funding, the number of Founders remaining

in the CEO position declines dramatically from over one-half to under

one-third.

-- Severance Packages: 72% of non-founding CEOs have some form of a

severance package. Of those with severance packages, the average

severance period is 12 months.

-- Board Compensation: On average, board members are granted 0.45% of

fully diluted equity to join the board. Very few outside board members

of private companies receive cash compensation.

Methodology

The proprietary study of executive equity and cash compensation provides authoritative compensation data for 13 top management positions, examining the evolution of executive pay as companies advance from start-ups to fully developed private enterprises. The study's results provide essential

information for businesses and investors to stay abreast of current trends in senior executive compensation and trends in organizational structures.

One hundred sixty-six privately-held life sciences and medical device companies throughout the United States took part in the survey which delved into the compensation and bonus equity packages of 13 key executive positions, including Chief Executive Officer, President/Chief Operating Officer, Chief Financial Officer, Chief Scientific Officer/Head of Research & Development, Chief Business Officer/Head of Business Development, Heads of Clinical Research, Regulatory Affairs, Manufacturing, Sales, Marketing, Engineering, Human Resources, and Chief Technology Officer. Data is analyzed in aggregate with detailed views by position looking at: product stage, headcount, geography, business segment, and number of financing rounds raised.

J. Robert Scott

J. Robert Scott is a retainer-based executive search firm and a portfolio company of Devonshire Investors, which is wholly owned by Fidelity Investments. The firm specializes in recruiting senior level executives for a wide array of international companies in the life sciences, technology, financial services, and higher education/not for profit fields. J. Robert Scott is headquartered in Boston, Massachusetts with international offices in Hong Kong and Singapore. Additional information about the firm can be found at http://www.j-robert-scott.com.

Ernst & Young

Ernst & Young is a global leader in assurance, tax, transaction and advisory services. Worldwide, our 130,000 people are united by our shared values and an unwavering commitment to quality. For more information, please visit http://www.ey.com.

Ernst & Young refers to the global organization of member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients.

This news release has been issued by EYGM Limited, a member of the global Ernst & Young organization that also does not provide any services to clients.

Wilmer Cutler Pickering Hale and Dorr LLP

WilmerHale is recognized globally for its premier practices in antitrust and competition; aviation; bankruptcy; civil and criminal trial and appellate litigation (including white collar defense); communications; corporate (including public offerings, public company counseling, start-up companies, venture capital, mergers and acquisitions, and licensing); defense and national security; financial institutions; intellectual property counseling and litigation; international arbitration; life sciences; securities regulation, enforcement and litigation; tax; and trade. With a longstanding commitment to public service, WilmerHale is renowned as a leader in pro bono representation. The firm has more than 1,100 lawyers, and offices worldwide in Baltimore, Beijing, Berlin, Boston, Brussels, London, Los Angeles, New York, Oxford, Palo Alto, Waltham and Washington. For more information, please visit our website at http://www.wilmerhale.com.


'/>"/>
SOURCE J. Robert Scott
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
2. Edwards Lifesciences to Present at the Bear Stearns 20th Annual Healthcare Conference
3. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
4. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
5. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
6. Novavax CEO to Present at the 2007 UBS Global Life Sciences Conference
7. Cardiac Science to Present at the UBS Global Life Sciences Conference
8. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
9. DRAXIS to Present at the 2007 UBS Global Life Sciences Conference
10. ViroPharma to Present at the UBS Global Life Sciences Conference
11. Clarient to Present at the UBS 2007 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room ... Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... HILLS, Calif. , June 23, 2016 Any ... the many challenges of the current process. Many of them ... because of the technical difficulties and high laboratory costs involved. ... have to offer it at such a high cost that ... afford it. Dr. Parsa Zadeh , founder ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Issue 52" report to their offering. ... treatment creates a favourable commercial environment for MedImmune to enter. ... base that will serve to drive considerable growth for effective ... serve to cap sales considerably, but development is still in ...
Breaking Medicine Technology: